Astria Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Astria Therapeutics (NASDAQ:ATXS) announced participation in two investor conferences. The company will present on March 17, 2022, at Oppenheimer’s 32nd Annual Healthcare Conference, featuring CEO Jill C. Milne discussing their lead program STAR-0215 for hereditary angioedema. Additionally, Astria will be involved in the Guggenheim Healthcare Talks on March 31 and April 1, 2022. A live webcast of the Oppenheimer presentation will be available, with an archive accessible for 30 days post-event. Astria Therapeutics is focused on developing therapies for rare allergic and immunological diseases.
Positive
None.
Negative
None.
Insights
Analyzing...
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that the Company will be participating in two upcoming investor conferences:
Oppenheimer’s 32nd Annual Healthcare Conference: On March 17, 2022 at 12:40pm ET, Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215.
Guggenheim Healthcare Talks, 2022 Genomic Medicines and Rare Disease: Astria Therapeutics will be participating in the conference, which will take place on March 31 and April 1, 2022.
A live webcast of the Oppenheimer presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer20/atxs/2810304. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.